Tackling Recalcitrant Pseudomonas aeruginosa Infections In Critical Illness via Anti-virulence Monotherapy
V. K. SINGH, M. Almpani, D. Maura, T. Kitao, L. Ferrari, S. Fontana, G. Bergamini, E. Calcaterra, C. Pignaffo, M. Negri, T. d. Oliveira Pereira, F. Skinner, M. Gkikas, D. Andreotti, A. Felici, , L. G. Rahme
This study identifies novel anti-MvfR compounds (NAMs) that reduce intestinal permeability and inflammation in Pseudomonas aeruginosa infections, offering a potential monotherapy for critical illness.
bioRxiv · Apr 27, 2022Microbiology